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ISPOR-SMDM Task Force’s Recommendations for Good ModelingWe appreciate the thoughtful letter regarding the validation topic
included among our articles reporting the ISPOR-SMDM task
force’s recommendations for good modeling practices.
Quite a bit of consideration was given by task force members
to terminology, not just regarding validation. “Accuracy” was
chosen because it is a nontechnical term that expresses how
closely a model is able to reﬂect reality (a natural and available
benchmark). It was used in the context of “judging a model’s
accuracy in making relevant predictions” to deﬁne “validity”; in
other words, an opinion or estimation of how “proper” and
“sufﬁcient” the model is in reﬂecting reality or representing the
intended system. Another possibility was “credibility”; and
indeed, this is the term being used in the ISPOR-AMCP-NPC
quality assurance questionnaires that are in user testing at
present. These terms reﬂect the overarching concept of reprodu-
cible, transparent research as underscored in another commen-
tary on our recommendations [1]. More important than the terms
chosen, however, is that the concepts be clear and understood.
Both the concepts of “properness” and “sufﬁciency” of represen-
tation are extensively discussed in the article.
We agree that validation should always be incorporated into
the modeling process, attending to face validity with stake-
holders and clinical experts; to veriﬁcation using a variety of
methods including double coding to ensure accurate calculations;
and to comparisons with other data to document how well the
model predictions ﬁt. By “single-use,” we did not mean that the
validation should be done once at a single point in time; rather,
we referred to models used to examine only one question in a
particular disease. “Multiuse” referred to a model developed for
use across many questions over time. In such cases, model
validation should be assessed for each use.
We welcome ongoing discussions and suggestions to reﬁne
and improve these deﬁnitions and to enhance the validity of
decision-analytic models going forward.
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